FDA Acknowledges Ligand Innovation Global’s Application for Emergency Use Authorization of LifeAir/VitaCaeli
Forwardly, Inc. (OTCMKT: FORW) announced that its subsidiary, Ligand Innovation Global, has submitted an application to the FDA for Emergency Use Authorization of the LifeAir Portable Ventilator. This application marks over a year of dedication from the partnership, with a focus on providing cost-effective ventilators to the market. Ligand's CEO emphasized the commitment to innovation, while Forwardly's CEO highlighted the financial backing that made this venture possible. The FDA's decision on the application is awaited.
- Application for Emergency Use Authorization submitted for LifeAir Portable Ventilator.
- Partnership with Ligand represents over a year of dedicated development.
- Focus on providing cost-effective ventilators to hospitals and emergency sites.
- Awaiting FDA's decision poses uncertainty regarding product availability.
Henderson, NV, March 03, 2022 (GLOBE NEWSWIRE) -- Forwardly, Inc. (OTCMKT: FORW) announced today that its partially owned subsidiary and partner, Ligand Innovation Global (“Ligand”), has received acknowledgment of receipt of its application for Emergency Use Authorization of the LifeAir Portable Ventilator, also known as the VitaCaeli Portable Ventilator, by the United States Food and Drug Administration (“FDA”). The company is now awaiting a decision or request for further information from the FDA.
The application was submitted to the FDA by Ligand’s attorneys and consultants, Hogan Lovells US LLP.
Ligand CEO, Dr. Dayo Olakulehin, stated, “The submission to the FDA represents over a year of dedication to the project by the Ligand-Forwardly partnership and our commitment to bring portable, cost-effective ventilators to the mass market.”
Forwardly CEO, George Sharp, commented, “Our funders made it possible to finance the development of the latest iteration of the ventilator with the goal of mutual benefit to both the Forwardly investors and the medical community at large”.
About Ligand Innovation Global, Inc.
Ligand IG continues development of the LifeAir G1 Emergency Portable Ventilator, also known as the VitaCaeli Portable Ventilator to address the expense of conventional ventilator systems which require the intubation and sedation of the patient. Ligand IG expects these units to become readily available, at a greatly reduced cost, to hospitals, nursing homes, and other sites where emergency, life-saving equipment, such as defibrillators are a necessity. Additional information regarding Ligand IG can be found at www.LigandGlobal.com.
About Forwardly, Inc.
Forwardly is an opportunity investor seeking to partner in fresh ideas. The company is headed by George Sharp, a longtime whistleblower, advocate against microcap fraud, and defender of shareholder rights. In addition to his continued participation in these activities, Mr. Sharp consults to public companies, attorneys and those associated with the financial markets. He is also a former consultant to OTC Markets Group, Inc. Further information about Forwardly, Inc. can be obtained through its website at www.ForwardlyPlaced.com
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Forwardly, Inc.
3535 Executive Terminal Drive
Suite 110
Henderson, NV 89052
702-840-4433
FAQ
What is the status of FORW's application to the FDA for the LifeAir Portable Ventilator?
When was the application for the LifeAir Portable Ventilator submitted to the FDA?
Who is involved in the development of the LifeAir Portable Ventilator?
What are the potential benefits of the LifeAir Portable Ventilator?
What is the stock symbol for Forwardly, Inc.?
